Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
UncategorizedApril 1, 2022
Our employees are passionate, innovative, and collaborative. Together, we strive to relieve suffering for people with great needs, but few options.
Tardive dyskenisia (TD) is estimated to affect approximately 600,000 people in the U.S. Although it can look or feel different from day to day, TD is a chronic condition and symptoms may be persistent.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) financial results for the second quarter ended June 30, 2022 and reiterated financial guidance for 2022.